Animal study · mice

P21 reduced tau buildup and cognitive deficits in Alzheimer's mice

Checked against the paper Animal studyPublished by PepVault

The takeaway

In Alzheimer's model mice, a year of oral P21 eased tau and soluble amyloid changes and restored cognition, which is preclinical evidence only.

Kind
Animal study
Studied in
Mice
Published
2014
Journal
Neurobiol Dis

What they tested

The team tested whether long-term oral P21, a peptide derived from ciliary neurotrophic factor (CNTF, a protein that supports nerve cells), could change the underlying disease in a mouse model of Alzheimer's disease.

How the study was done

A study in female mice: 3xTg-AD mice, a triple transgenic model of Alzheimer's disease, and normal (wild type) mice. Starting at 9-10 months of age, the mice ate a diet with P21 or a plain control diet for 12 months, which covered moderate and severe stages of the disease.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking P21? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the Alzheimer's model mice, P21 significantly reduced abnormal tau phosphorylation and buildup at sites tied to the tangles seen in Alzheimer's disease. For amyloid beta (Aβ, the protein in Alzheimer's plaques), P21 significantly lowered soluble Aβ levels, and plaque load in the CA1 area of the hippocampus showed only a trend toward reduction. Treated model mice had higher BDNF (brain-derived neurotrophic factor, a protein that supports nerve cells) and lower GSK3β activity, which the authors see as the likely route of the effect. P21 also rescued deficits in cognition, in neurogenesis (the making of new nerve cells), and in synaptic plasticity (how well connections between nerve cells adapt) in these mice.

What it doesn’t show

This is mouse work in a single genetic model of Alzheimer's disease, using only female mice, so it is not a result in people. The plaque change did not reach significance, and the BDNF and GSK3β link is the authors' proposed explanation, not a tested cause.

The paper

Kazim et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014.

The compound

More studies on P21

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking P21? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo